Article Text

Download PDFPDF

Detection of myositis-specific antibodies
  1. Jean-Baptiste Vulsteke1,
  2. Ellen De Langhe2,3,
  3. Kristl G Claeys4,5,6,
  4. Doreen Dillaerts7,
  5. Koen Poesen8,9,
  6. Jan Lenaerts2,
  7. René Westhovens2,3,
  8. Philip Van Damme4,10,
  9. Daniel Blockmans1,
  10. Petra De Haes11,
  11. Xavier Bossuyt7,9
  1. 1 Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium
  2. 2 Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium
  3. 3 Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
  4. 4 Department of Neurology, University Hospitals Leuven, Leuven, Belgium
  5. 5 Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven, Leuven, Belgium
  6. 6 Department of Neurology and Institute of Neuropathology, University Hospital RWTH Aachen, Aachen, Germany
  7. 7 Department of Microbiology and Immunology, Experimental Laboratory Immunology, KU Leuven, Leuven, Belgium
  8. 8 Laboratory for Molecular Neurobiomarker Research, KU Leuven, Leuven, Belgium
  9. 9 Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
  10. 10 Department of Neurosciences, Experimental Neurology, VIB Center for Brain & Disease Research, Laboratory of Neurobiology, KU Leuven, Leuven, Belgium
  11. 11 Department of Dermatology, University Hospitals Leuven, Leuven, Belgium
  1. Correspondence to Dr Xavier Bossuyt, Laboratory Medicine, University Hospitals Gasthuisberg, Leuven 3000, Belgium; xavier.bossuyt{at}

Statistics from

It was with much interest that we read the recent European League Against Rheumatism/American College of Rheumatology classification criteria for idiopathic inflammatory myopathies.1 These criteria include Jo-1 autoantibodies, and the authors discussed that future updates of the criteria should also include the more recently identified myositis-specific autoantibodies.1 2 The interest in autoantibodies for classification is also illustrated by a recent proposal for a new clinicoserological classification of adult autoimmune myositis, which is based on the association of autoantibodies with distinct clinical phenotypes.3 4 For example, antibodies to synthetases (eg, Jo-1, PL-7 and PL-12) define the antisynthetase syndrome, anti-MDA-5 antibodies are associated with myositis with overlap features such as interstitial lung disease, anti-TIF-1γ and anti-NXP-2 define a subgroup of dermatomyositis and anti-SRP and anti-HMGCR are associated with necrotising autoimmune myositis.2

As autoantibodies play a role in the newly proposed classifications,1 …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles